18 results about "CXCL1" patented technology

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.

The application provides a combined drug, a liposome, a biomimetic liposome, a preparation method of the combined drug, the liposome and the biomimetic liposome, and application of the combined drug, the liposome and the biomimetic liposome in preparation of an anti-breast cancer lung metastasis drug, and belongs to the technical field of biological medicines. The combined drug comprises panatinib and ginsenoside Rg3. The application further provides a liposome PNT-Rg3-Lipo for simultaneously loading the two, and a biomimetic liposome MM / PNT-Rg3-Lipo coated with a macrophage membrane. Experiments show that the combination of the two can synergistically regulate chemokines CXCL1 , CXCL2 and CXCL11 , and the effect is better than the sum of the single use. The MM / PNT-Rg3-Lipo has uniform particle size, retains integrin alpha 4 / beta 1 functional proteins, can target lung metastases, significantly reduces metastatic nodules, and has good biocompatibility. The application provides an effective new strategy for resisting breast cancer lung metastasis.

This invention discloses a bispecific nanobody targeting CXCL1 and PD-L1 and its applications, belonging to the fields of antibody engineering and bioengineering technology. The bispecific nanobody targeting CXCL1 and PD-L1 comprises at least one nanobody recognizing CXCL1 and one nanobody recognizing PD-L1, with the nanobody monomers linked by a linker. The bispecific nanobody targeting PD-L1 / CXCL1 provided by this invention has a unique structure, enabling it to specifically recognize and bind to both CXCL1 and PD-L1. It achieves an affinity of 1.08 nM for CXCL1 and 1.09 nM for PD-L1, effectively preventing immune escape-induced resistance to antibody therapy, making it suitable for a wider range of patients, and providing a new approach for CRC treatment.

The inventors' primary objective was to provide a technology for screening materials that can suppress inflammation, particularly in aging tissues. [Solution] The above problem can be solved by a method that includes step B: contacting vascular endothelial cells that have been passaged 15 or more times with a test substance, and step C: evaluating the expression level of at least one inflammation-related factor selected from the group consisting of IL-6, IL-8, CXCL1, PAI-1, MMP-1, ICAM-1, VCAM-1, E-selectin, and CCL2 in the vascular endothelial cells that were contacted with the test substance in step B.

The present disclosure provides methods of predicting / diagnosing immunotherapeutic toxicity in a subject using levels of at least one biomarker protein in a biological sample from the subject, wherein the at least one biomarker protein comprises C4orf47, CXCL1, LMNTD2, ERVV-1, PSRC1, SPRED2, KIF22, MRRF, DAAM1, ABO, MAP9, or any combination thereof. Also provided herein are methods of determining therapeutic regimens for patients based on the biomarker levels.

Methods for treating or inhibiting fibrosis in a subject by administering specific chemokine cocktails are described. The chemokine cocktails include combinations of CXCL4, CXCL9, CXCL10, CXCL11 and / or CXCL12 proteins, or the combination of CXCL1 and CXCL8 proteins. Methods for increasing extracellular matrix (ECM) production and / or treating a wound in a subject by administering specific chemokine cocktails are also described. In these methods, the cocktails include CXCL1 and CXCL8 proteins and optionally further include a CCL2 protein.

The application provides a use of biomarkers in the preparation of a product for TCM syndrome typing of a type 2 diabetes mellitus patient combined with metabolic syndrome, and / or for evaluating the risk of cognitive impairment of a type 2 diabetes mellitus patient combined with metabolic syndrome, wherein the biomarkers are selected from one or more of SERPINA3, BACE1 or CXCL1. The serum SERPINA3, BACE1 and CXCL1 levels are related to TCM syndrome types, provide a laboratory basis for TCM syndrome differentiation and treatment, help to improve the accuracy and standardization of TCM diagnosis, and according to the serum index levels and characteristics, a personalized treatment plan is formulated. Secondly, the serum index has predictive value for cognitive impairment, which helps to identify high-risk patients early and delay cognitive decline. For patients with a long course and poor blood glucose control, the serum index level can be regularly detected, combined with clinical indications, and timely anti-inflammatory, nerve nutrition and insulin resistance improvement treatment is given to protect cognitive function.

The invention belongs to the technical field of biological medicines, and particularly relates to application of IAA in preparation of a medicine for preventing and treating atherosclerosis. Atherosclerosis is caused by excessive deposition of cholesterol, and IAA can significantly reduce formation of aorta and aortic sinus lipid plaques of atherosclerosis model mice by adjusting monocyte chemotactic and adhesion functions (specifically, down-regulating expression of chemotactic factors CCL2 and CXCL1, receptors CCR1 and CCR2, adhesion molecules ICAM1 and the like). An injection preparation is preferably selected as a medicine dosage form, the intervention dosage of IAA is 50 mg / kg, and the intervention time is 15 weeks. The new application of IAA in prevention and treatment of atherosclerosis is explored for the first time, the action mechanism of IAA is clear, the intervention effect is remarkable, and a new target spot and thought are provided for developing safe and effective medicines and means for preventing and treating atherosclerosis.

The invention discloses a natural small molecule composition targeting CXCL1 and application of the natural small molecule composition in triple negative breast cancer immunotherapy. Experiments find that a natural small molecule composition composed of specnuezhenide, icariin and cryptotanshinone remodels a triple-negative breast cancer (TNBC) immune microenvironment by synergistically inhibiting a TAMs / CXCL1 synthesis-degradation-secretion full pathway under a specific ratio, can significantly improve the triple-negative breast cancer immunotherapy effect, and has a broad application prospect. Therefore, the invention provides a new way for developing medicines for efficiently treating the triple-negative breast cancer.

The invention discloses an application of CXCL1 in diagnosis of a calcified aortic valve disease. According to the invention, it is found for the first time that CXCL1 can be used in early diagnosis of calcified aortic valve disease (CAVD), and it is found through verification of a real clinical sample collected by the invention that CXCL1 has good diagnosis efficiency on diagnosis of CAVD, and the accuracy, sensitivity and specificity are all high. The invention provides a new thought and strategy for the technical field of CAVD diagnosis, and has important scientific significance and clinical application value.

The invention provides an application of an IL-17REL fusion protein in treatment of an autoimmune disease. Specifically, the IL-17REL fusion protein disclosed by the invention can be specifically combined with IL-17A, IL-17C and IL-17F in IL-17 family members, and the expression of downstream inflammatory factors such as IL1beta, IL6, CXCL1 and CXCL2 is inhibited, so that the inflammation is inhibited, and the effect of treating the autoimmune disease is realized.

The invention discloses application of andrographolide and a pharmaceutical composition thereof in preparation of a medicine for preventing and / or treating lung cancer, particularly lung metastatic tumor, and belongs to the technical field of medicine. In-vivo and in-vitro experiments of a system prove that andrographolide can inhibit activation of a nuclear factor kappa B (NF-kappa B) signal channel by down-regulating expression of glycogen synthase kinase 3beta (GSK3beta), and particularly, phosphorylation and nuclear translocation processes of an NF-kappa B p65 subunit Ser536 site are inhibited. According to the effect, transcription and expression of downstream target gene chemotactic factors CCL2 and CXCL1 are effectively reduced, finally, infiltration of tumor-related macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in tumor tissue is remarkably reduced, aggregation of anti-tumor immune cells such as CD8 + T cells is promoted, an immunosuppressive microenvironment is reversed into an immune activation state, and the immunosuppressive activity of tumor cells is improved. And lung cancer metastasis is inhibited from the source. The invention provides a brand new candidate drug and a clear action mechanism for clinical prevention and treatment of lung cancer metastasis, and has a good development prospect.

The present application provides a compound probiotic capable of alleviating gouty arthritis and the use thereof. The compound probiotic capable of alleviating gouty arthritis consists of a Bifidobacterium longum BL21 strain and a Lactobacillus salivarius LS97 strain. The present application has discovered that the two strains can work together, mutually promote each other, and exhibit a synergistic effect in alleviating gouty arthritis. The synergistic effect is specifically demonstrated by the following: the ability to reduce pain-sensitive reactivity; the ability to decrease the number of white blood cells and the aggregation of neutrophils in joints; the ability to lower the activity of myeloperoxidase in periarticular tissues; the ability to reduce the production of the inflammatory factors CXCL1 and IL-1β; and the ability to increase the expression level of the anti-inflammatory cytokine IL-10 in joint tissues.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

The invention discloses a serum protein marker group for colorectal cancer diagnosis and application thereof, and relates to the technical field of molecular diagnosis. According to the invention, the content of 92 tumor immune-related circulating proteins such as IL-8, TNFRSF9, TIE2 and the like is detected by using a PEA circulating proteomics platform; establishing a signal model by using an elastic network regression method, and performing model performance verification by applying multiple iterations of cross validation; according to the present invention, the optimal signal model composed of 6 proteins (IL7, CXCL12, IL10, IL15, CXCL1 and MCP-3) is mined, and the optimal signal model has high sensitivity and high specificity in the distinguishing of the straight carcinoma patient and the healthy control person, and can be used for the non-invasive early diagnosis of the colorectal cancer. Detection can be carried out through a whole blood sample, sampling is convenient, and the early detection rate of colorectal cancer can be effectively increased in time.

The invention provides an anti-ELR + CXC chemotactic factor antibody or an antigen binding fragment thereof as well as a preparation method and application of the anti-ELR + CXC chemotactic factor antibody. The ELR + CXC chemotactic factor antibody or the antigen binding fragment thereof. The ELR + CXC chemotactic factor is selected from one or more of CXCL1, CXCL2, CXCL3 and CXCL8. According to the application, the antibody which is specifically combined with the ELR + CXC chemotactic factor strongly related to the disease is screened out, the antibody can block a signal channel of the ELR + CXC chemotactic factor, ERK phosphorylation and human neutrophil chemotactic activity are blocked, and a new feasible scheme is provided for treatment of inflammation, immune diseases and cancers.

The present invention relates to a composition for preventing, ameliorating, or treating kidney and liver diseases, comprising a complex (NEPROBIN) of Ganoderma lucidum extract and Robinia pseudoacacia flower extract as an active ingredient. The complex provided from the present invention exhibits excellent effects in preventing kidney damage, maintaining kidney function, and regenerating kidney tissue by means of inhibition of NO production, reduction in cytokine (TNF-a) and Crp gene expression, increase in glutathione, reduction in ROS production, and increase in uremic toxin excretion, and exhibits excellent effects in preventing liver damage and improving liver function by means of inhibition of NO production, reduction in cytokine (IL6) and MCP1 and CXCL1 gene expression, increase in glutathione, suppression of expression of fibrosis markers (ACTA2, Vim, COL3A1) of hepatic stellate cells, restoration of GSH in liver tissue, increase in antioxidant enzyme activity, and suppression of expression of antiinflammatory- and antifibrotic-related genes and proteins, and thus, the complex is applicable as a pharmaceutical composition for preventing or treating kidney and / or liver diseases, and as a health functional food and food composition for preventing or ameliorating liver diseases.

The invention provides an application of an IL-17REL fusion protein in treatment of an inflammatory bowel disease. Specifically, the IL-17REL fusion protein disclosed by the invention can be specifically combined with IL-17A, IL-17C and IL-17F in IL-17 family members, and the expression of downstream inflammatory factors such as IL1beta, IL6, CXCL1 and CXCL2 is inhibited, so that the inflammation is inhibited, and the effect of treating the inflammatory bowel disease is realized.